BIOMAT Database Logo BIOMAT Database Logo

Superiority of protease inhibitors over nonnucleoside reverse-transcriptase inhibitors when highly active antiretroviral therapy is resumed after treatment interruption. 2005

Pablo Barreiro, and Carmen de Mendoza, and Juan González-Lahoz, and Vincent Soriano
Service of Infectious Diseases, Hospital Carlos III, Madrid, Spain.

Forty-five human immunodeficiency virus (HIV)-infected patients stopped taking treatment but resumed taking it thereafter. All 11 who resumed treatment with their prior protease inhibitor (PI)-based regimen reattained an undetectable virus load, whereas this occurred for only 15 (44%) of 34 patients who resumed nonnucleoside reverse-transcriptase inhibitor (NNRTI)-based treatment (P<.001). Distinct pharmacokinetics and resistance barriers may result in different performances for PIs and NNRTIs after treatment interruptions.

UI MeSH Term Description Entries
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012189 Retrospective Studies Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons. Retrospective Study,Studies, Retrospective,Study, Retrospective
D012367 RNA, Viral Ribonucleic acid that makes up the genetic material of viruses. Viral RNA
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human
D017320 HIV Protease Inhibitors Inhibitors of HIV PROTEASE, an enzyme required for production of proteins needed for viral assembly. HIV Protease Inhibitor,Inhibitor, HIV Protease,Inhibitors, HIV Protease,Protease Inhibitor, HIV,Protease Inhibitors, HIV
D018791 CD4 Lymphocyte Count The number of CD4-POSITIVE T-LYMPHOCYTES per unit volume of BLOOD. Determination requires the use of a fluorescence-activated flow cytometer. Lymphocyte Count, CD4,T4 Lymphocyte Count,CD4 Cell Counts,CD4 Counts,CD4+ Cell Counts,CD4+ Counts,CD4 Cell Count,CD4 Count,CD4 Lymphocyte Counts,CD4+ Cell Count,CD4+ Count,Count, T4 Lymphocyte,Counts, T4 Lymphocyte,Lymphocyte Count, T4,Lymphocyte Counts, CD4,Lymphocyte Counts, T4,T4 Lymphocyte Counts
D018894 Reverse Transcriptase Inhibitors Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. Reverse Transcriptase Inhibitor,Inhibitors, Reverse Transcriptase,Inhibitor, Reverse Transcriptase,Transcriptase Inhibitor, Reverse
D019562 Viral Load The quantity of measurable virus in a body fluid. Change in viral load, measured in plasma, is sometimes used as a SURROGATE MARKER in disease progression. Viral Burden,Virus Titer,Burden, Viral,Load, Viral,Titer, Virus
D023241 Antiretroviral Therapy, Highly Active Drug regimens, for patients with HIV INFECTIONS, that aggressively suppress HIV replication. The regimens usually involve administration of three or more different drugs including a protease inhibitor. Combination Antiretroviral Therapy,HAART,Highly Active Antiretroviral Therapy,Antiretroviral Therapies, Combination,Antiretroviral Therapy, Combination,Combination Antiretroviral Therapies,Therapies, Combination Antiretroviral,Therapy, Combination Antiretroviral

Related Publications

Pablo Barreiro, and Carmen de Mendoza, and Juan González-Lahoz, and Vincent Soriano
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
February 2004, Antimicrobial agents and chemotherapy,
Pablo Barreiro, and Carmen de Mendoza, and Juan González-Lahoz, and Vincent Soriano
Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviral-naïve persons starting treatment.
October 2020, HIV medicine,
Pablo Barreiro, and Carmen de Mendoza, and Juan González-Lahoz, and Vincent Soriano
The nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors in the treatment of HIV infections (AIDS).
January 2013, Advances in pharmacology (San Diego, Calif.),
Pablo Barreiro, and Carmen de Mendoza, and Juan González-Lahoz, and Vincent Soriano
Nonnucleoside reverse transcriptase inhibitors.
October 1997, AIDS clinical care,
Pablo Barreiro, and Carmen de Mendoza, and Juan González-Lahoz, and Vincent Soriano
CD4 cell count response to nonnucleoside reverse transcriptase inhibitor- or protease inhibitor-based highly active antiretroviral therapy in an observational cohort study.
November 2003, Journal of acquired immune deficiency syndromes (1999),
Pablo Barreiro, and Carmen de Mendoza, and Juan González-Lahoz, and Vincent Soriano
New nonnucleoside reverse transcriptase inhibitors.
February 1999, GMHC treatment issues : the Gay Men's Health Crisis newsletter of experimental AIDS therapies,
Pablo Barreiro, and Carmen de Mendoza, and Juan González-Lahoz, and Vincent Soriano
Use of nonnucleoside reverse-transcriptase inhibitors.
February 1998, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists,
Pablo Barreiro, and Carmen de Mendoza, and Juan González-Lahoz, and Vincent Soriano
Future of nonnucleoside reverse transcriptase inhibitors.
January 2018, Proceedings of the National Academy of Sciences of the United States of America,
Pablo Barreiro, and Carmen de Mendoza, and Juan González-Lahoz, and Vincent Soriano
Immunological analysis of treatment interruption after early highly active antiretroviral therapy.
December 2010, Viral immunology,
Pablo Barreiro, and Carmen de Mendoza, and Juan González-Lahoz, and Vincent Soriano
Highly active antiretroviral treatment against STLV-1 infection combining reverse transcriptase and HDAC inhibitors.
November 2010, Blood,
Copied contents to your clipboard!